Stock Taper
SCREENER COMPARE ANY 2 STOCKS
JNJ
JOHNSON & JOHNSON
NYSE
$271.27
▲ UP 2.04% (5.42)

KEY STATISTICS

Market Cap$653.42 B
52w High$276.47
52w Low$173.33
Dividend Yield2.11%
FrequencyQuarterly
P/E25.28
Volume3.62M
Shares Out.2.41B

COMPANY

LEADERSHIP

Joaquin Duato
CHIEF EXECUTIVE
Joaquin Duato

COMPENSATION 2026

Salary$1,600,000
Stock Awards$15,028,948
Incentive Plan Pay$4,298,700
All Other Comp.$601,231
Total$32,758,111

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 2, 1962
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
141,700

PRICE TARGET

Target High$305.00
Target Low$255.00
Target Median$282.00
Target Consensus$282.08

UPCOMING EARNINGS

DateOct 13, 2026
DayTuesday
Rev. Est.$25.32B
OCT
13
TUE

SPLIT RECORD

DATETYPERATIO
2001-06-13Forward2:1
1996-06-12Forward2:1
1992-06-10Forward2:1
1989-05-11Forward2:1
1981-05-19Forward3:1
1970-05-18Forward3:1
1967-06-19Forward3:1

PRICE

$271.27 ▲ UP 2.04% (+$5.42)
OVERLAYS
$267$269$270$2729:32 AM10:35 AM11:37 AM12:40 PM1:43 PM2:45 PM3:48 PM271.27

About Johnson & Johnson

https://www.jnj.com ↗

Johnson & Johnson, now focused on innovative medicines and medical devices after spinning off its consumer health brands into Kenvue in 2023, develops and sells healthcare products worldwide to advance human health.

INDUSTRY

Drug Manufacturers - General

A PRODUCT JOHNSON & JOHNSON IS KNOWN FOR

Darzalex (daratumumab)
Darzalex (daratumumab)

Darzalex, Johnson & Johnson’s top-selling blood cancer medication, generated $11.7 billion in 2024, marking significant growth and solidifying its role as a key product in the company's oncology portfolio.

COMPETITORS

COMPETITOR
AMGN COMPARE
BMY COMPARE
PFE COMPARE
SNY COMPARE
TAK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Innovative Medicine$15.56B $15.76B ▲$15.43B ▼$16.38B ▲
MedTech$8.43B $8.8B ▲$8.64B ▼$8.93B ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES— $27.9B — —
Europe$5.44B $5.6B ▲$5.85B ▲$5.73B ▼
AsiaPacific Africa$3.61B $3.5B ▼$3.59B ▲$3.74B ▲
Western Hemisphere excluding US$1.23B $1.27B ▲$1.29B ▲$1.31B ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
1,294
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.85% · 76.7M
XUS.TO
0.97% · 32.1M
SPY
0.97% · 29.5M
SPMO
4.72% · 3.9M
JEPI
1.77% · 3.1M
SCHX
0.93% · 2.6M
DFUV
2.84% · 1.7M
DGRW
2.38% · 1.5M
EGV2.DE
1.52% · 1.5M
FHLC
8.88% · 1.2M
XDWH.L
7.53% · 1.1M
XZ
XZME.F
2.30% · 824.8K
QLTY
5.10% · 764.9K
ZSP.TO
0.97% · 750.8K
NOBL
1.47% · 650.7K
USMC
3.28% · 622.2K
FTCS
2.03% · 601.9K
HMWA.L
0.69% · 500.6K
GSLC
0.86% · 487.1K
QUAL.AX
2.00% · 469.2K
UBU7.DE
0.70% · 457.4K
SPYI
0.98% · 431.7K
PB
PBPH
9.60% · 368.7K
AVUS
0.66% · 356.2K
BGIG
4.15% · 344.7K
QDF
2.90% · 274.9K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
48.95%
HOLDERS
5,960
TOP 12 OF 5,960 · RANKED BY POSITION SIZE
Vanguard Group Inc
240.3M sh · $49.74B
Blackrock, Inc.
213.4M sh · $52.16B
Blackrock Inc.
198.2M sh · $28.97B
State Street Corp
133.9M sh · $27.7B
Blackrock Institutional Trust Company, N.A.
74.8M sh · $8.62B
Jpmorgan Chase & Co
63.1M sh · $15.3B
Geode Capital Management, LLC
59.2M sh · $14.42B
Morgan Stanley
48.2M sh · $8.94B
Blackrock Fund Advisors
45.5M sh · $5.25B
State Farm Investment Management Corp
37.9M sh · $2.27M
Norges Bank
33.5M sh · $6.92B
State Farm Mutual Automobile Insurance Co
31.6M sh · $5.86B

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity5
Return On Assets5
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Ro Khanna
Ro Khanna
Purchase
2026-04-13
 Thomas H. Kean
Thomas H. Kean
Sale
2026-03-26
SENATE TRADES
John Boozman
John Boozman
Sale
2026-03-19
HOUSE TRADES
Rich McCormick
Rich McCormick
Sale
2026-03-19

INSIDER TRADES

★
OFFICER: EVP, WWC. INNOVATIVE MEDICINE
Taubert Jennifer L
Purchase · 15.0K shares
2026-08-17
★
OFFICER: EVP, WWC. INNOVATIVE MEDICINE
Taubert Jennifer L
Sale · 15.0K shares
2026-08-17
★
DIRECTOR, OFFICER: CEO AND CHAIRMAN OF THE BOARD
Duato Joaquin
Sale · 123.3K shares
2026-08-13
★
DIRECTOR, OFFICER: CEO AND CHAIRMAN OF THE BOARD
Duato Joaquin
Sale · 102.3K shares
2026-08-13

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OUTPERFORM 3
HOLD 3
OVERWEIGHT 2
NEUTRAL 2
EQUAL WEIGHT 1
SECTOR OUTPERFORM 1
MARKET PERFORM 1
19 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY Wells Fargo OVERWEIGHT RBC Capital OUTPERFORM Morgan Stanley OVERWEIGHT Raymond James OUTPERFORM TD Cowen BUY B of A Securities NEUTRAL Citigroup BUY

SECTORS PEERS

PEERPRICE
ABBV$260.80COMPARE
MRK$149.16COMPARE
UNH$395.28COMPARE
NVS$161.62COMPARE
AZN$161.88COMPARE
AMGN$436.48COMPARE
NVO$45.26COMPARE
GILD$149.09COMPARE